TABLE 3.

Effect of baicalein treatment on relative mRNA abundance of adipogenesis-associated factors.

Effect1	AGPAT2	C/EBPα	C/EBPβ	DGAT2	PLIN1	PPARγ	SREBP1
Treatment
0 mg/kg	1.20b	0.93	0.93ab	1.52	1.23b	1.30	1.18b
125 mg/kg	1.75ab	2.00	0.52b	1.80	2.23b	1.21	1.14ab
250 mg/kg	3.17a	1.28	0.53b	1.42	5.27a	1.69	2.40a
500 mg/kg	1.39b	2.13	1.23a	2.24	1.86b	1.47	1.49ab
SEM	0.47	0.48	0.12	0.36	0.79	0.25	0.34
P-value	0.01	0.24	0.0001	0.38	0.001	0.53	0.03
Adipose depot
Subcutaneous	1.96	1.11	0.72	2.11	2.84	1.72	1.59
Abdominal	1.80	2.05	0.89	1.38	2.45	1.12	1.51
SEM	0.34	0.34	0.08	0.25	0.56	0.18	0.24
P-value	0.74	0.06	0.16	0.04	0.63	0.02	0.83
Treatment × adipose depot	0.25	0.26	0.41	0.66	0.52	0.56	0.42

¹Values represent least squares means and pooled standard errors of the means with associated P-values for the effect of dietary treatment, adipose tissue depot, and their interaction (n = 10). Different superscripts within an effect for each gene are significantly different at P < 0.05, Tukey’s test.

AGPAT2, 1-acylglycerol-3-phosphate-O-acyltransferase 2; C/EBPα, CCAAT/enhancer-binding protein alpha; C/EBPβ, CCAAT/enhancer-binding protein beta; DGAT2, diacylglycerol acyltransferase; PLIN1, perilipin-1; PPARγ, peroxisome proliferator-activated receptor gamma; SREBP1, sterol regulatory element-binding transcription factor 1.